New drug IMA402 targets tough cancers in early trial
Disease control
Recruiting now
This study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase: PHASE1, PHASE2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC